What clinical milestone did Imugene (ASX:IMU) recently announce?

Imugene (ASX:IMU) announced it has dosed the first patient in the Bruton Tyrosine Kinase inhibitor (BTKi) combination cohort of its ongoing Phase 1b basket study for azer-cel.

What is Imugene’s (ASX:IMU) azer-cel and how does it work?

Azer-cel is an "off-the-shelf" allogeneic CAR T-cell therapy designed to treat advanced blood cancers where there is a significant unmet medical need. This specific trial cohort is testing whether administering azer-cel concurrently with a BTKi can enhance therapeutic activity, safety, and preliminary efficacy in patients.

Why is Imugene (ASX:IMU) combining azer-cel with a BTKi?

While BTKi therapies are the established standard of care for B-cell malignancies like follicular lymphoma and chronic lymphocytic leukaemia, many patients eventually develop resistance or intolerance to them.

What is the market opportunity for Imugene’s (ASX:IMU) combination therapy?

The trial allows Imugene to target a massive and established commercial sector, as the global BTKi market reached approximately US$12 billion in 2025.

Where is the Imugene (ASX:IMU) clinical trial currently taking place?

Patient enrolment for this Phase 1b basket study is highly active and expanding globally. Recruitment is currently underway across ten specialised clinical sites in the United States and five clinical sites throughout Australia.

How risky is Imugene (ASX:IMU) as a retail investment after this news?

Imugene remains a highly speculative, high-risk investment because it is a clinical-stage biotechnology company with no commercialised products. While dosing the first patient is a positive operational step, the company must still navigate multiple phases of clinical trials, which carry a high rate of failure before regulatory approval can be achieved.

Image for illustrative purposes only. Not a real photo.

Imugene doses first azer-cel combination patient

Written by Liezl GambePublished May. 28 2026Last Updated May. 28 2026

Australian clinical-stage immuno-oncology company Imugene (ASX:IMU) announced a milestone in its ongoing Phase 1b basket study of azer-cel, dosing the first patient in its Bruton Tyrosine Kinase inhibitor combination cohort.

The pioneering treatment was administered at the prestigious Baylor University in Waco, Texas, to a patient suffering from mantle cell lymphoma who had previously failed standard BTKi therapy.

Azer-cel is an innovative, "off-the-shelf" allogeneic CAR T-cell therapy designed to target advanced blood cancers with massive unmet medical needs.

The specific third cohort is evaluating whether concurrent dosing of azer-cel alongside a BTKi can enhance therapeutic activity, safety, and preliminary efficacy.

While BTKi therapies represent an established standard of care for various B-cell malignancies—including follicular lymphoma, chronic lymphocytic leukaemia, and MCL—many patients eventually develop resistance or intolerance to the treatment.

The trial aims to overcome those hurdles, tapping into a global BTKi market that reached approximately US$12 billion in 2025.

By combining the therapies, researchers hope to provide a powerful new avenue for patients facing limited options.

Enrolment for the clinical study remains highly active, with patient recruitment currently expanding across ten specialised sites in the United States and five clinical sites throughout Australia.

At the time of reporting, Imugene’s share price was $0.11.